Skip to main content
NCBI home page
PLOS One logoLink to PLOS One
. 2022 Nov 29;17(11):e0278347. doi: 10.1371/journal.pone.0278347

Prevalence and correlates of pre-diabetes in adults of mixed ethnicities in the South African population: A systematic review and meta-analysis

Aubrey M Sosibo 1,*,#, Nomusa C Mzimela 1,‡, Phikelelani S Ngubane 1,‡, Andile Khathi 1,#
Editor: Paolo Magni2
PMCID: PMC9707763  PMID: 36445923

Abstract

Introduction

Pre-diabetes is a metabolic condition characterised by moderate glycaemic dysregulation and is a frontline risk factor for multiple metabolic complications such as type 2 diabetes mellitus. To the best of our knowledge, this will be the first systematic review and meta-analysis focusing on generating a comprehensive pooling of studies reporting on pre-diabetes prevalence in South Africa. Therefore, the review’s purpose will be to screen and select reports that can be used to synthesise and provide the best estimate prevalence of pre-diabetes and its associated correlates in the South African population.

Methods and analysis

To determine the prevalence and correlates of pre-diabetes in South Africa, we searched PubMed, Web of Science, Google scholar and African Journal online for published or unpublished studies reporting the prevalence of pre-diabetes in South Africa starting from the year 2000 to 2020. Studies were assessed for eligibility by checking if they met the inclusion criteria.

Results & conclusion

The total number of studies deemed eligible is 13 and from these studies, an overall prevalence of pre-diabetes was reported to be 15,56% in the South African population. Hypertension, obesity and sedentary lifestyle were the common correlates recorded for the population of interest. Therefore, the review highlights the disturbingly high prevalence of pre-diabetes in South Africa and necessitates further investigations into the possible genetics, biochemical and hormonal changes in pre-diabetes.

Ethics and dissemination

The review will not require ethics clearance because non-identifiable data will be used. The review outcomes will give insight into the current burden that pre-diabetes has in South Africa.

PROSPERO registration number

CRD42020182430

1. Introduction

Pre-diabetes is a condition that exists when the blood glucose concentration is higher than normal but not high enough to diagnose type 2 diabetes (T2D) [1, 2]. The diagnosis of pre-diabetes can be confirmed by impaired fasting glucose (IFG), impaired glucose tolerance (IGT) or glycated haemoglobin (HbA1c) [3]. The co-existence of moderate insulin resistance and beta-cell dysfunction characterises the pre-diabetic state [2, 3]. Pre-diabetes is associated with metabolic complications often observed in T2D, such as microvascular and macrovascular complications [4–7]. Presently, lifestyle intervention and the administration of metformin are the recommended treatments for pre-diabetes [1, 8, 9].

Interestingly, the pathophysiology of pre-diabetes in subjects with impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) displays different pathophysiological mechanisms [10, 11]. In people with IFG, hepatic insulin resistance is observed, while in those with IGT, muscular insulin resistance is seen [10]. In the liver cells, insulin will stimulate glycogen synthesis by activating the enzyme hexokinase, inducing the phosphorylation of glucose to glucose-6-phosphate. Simultaneously, insulin inhibits the gluconeogenesis process in the hepatic cells. However, in the IFG state, diminished insulin sensitivity in the hepatocytes will stimulate gluconeogenesis and glycogenolysis processes [11, 12]. Glucose concentration in the plasma will consequently rise.

The skeletal muscle insulin signalling pathway is initiated upon insulin binding to the α-subunit of the insulin receptor, which then causes the tyrosine residues in the intracellular β-domain of the insulin receptor to undergo autophosphorylation [13, 14]. After that, a cascade of events leads to the activation of Akt, which causes the translocation of the glucose transporter-4 (GLUT-4) to the plasma membrane, thereby allowing glucose uptake into the skeletal muscle tissue [14]. However, the insulin signalling pathway is impaired in the IGT state, resulting in glucose homeostasis dysregulation [11]. The consequences of leaving pre-diabetes unattended are significant.

Pre-diabetes is the frontline risk factor that can lead to the development of T2D [3]. This was amplified further by the American Diabetes Association (ADA) findings, which estimate that up to 70% of people with pre-diabetes will, in the long run, have T2D [15, 16]. In 2019, the global prevalence of diabetes stood at 463 million, while a further estimate of 578 million people is predicted to have T2D by 2035 [17, 18]. T2D is responsible for the deaths of approximately 1.5 million people annually [19]. In addition, other causes of fatalities, such as those related to cardiovascular disease and the more recent COVID-19 virus, occur in individuals in which diabetes exists as a comorbidity [20]. Therefore, understanding pre-diabetes can be pivotal in mitigating the incidence of T2D and the mortality rate. Consequently, this calls for further research to be conducted in investigating pre-diabetes.

The global prevalence of pre-diabetes or impaired glucose tolerance was estimated to be 7.5% (374 million) in 2019 and is projected to reach 8.0% (454 million) by 2030 [18]. Interestingly, some literature has documented the prevalence of diagnosed and undiagnosed pre-diabetes and how it affects different ethnic groups. A study by Geert Roeyen et al. showed that 77.7% of patients referred for pancreatic surgery had some degree of pre-diabetes [21]. Another report revealed that 15.3% of adults of the 88 million estimated to have pre-diabetes did not know, which indicates that most people remain with this condition undiagnosed [22]. This high number of undiagnosed pre-diabetes cases in people is a worrying matter because if it is left unchecked, the incidence of T2D will continue to rise [10]. Additionally, a published study conducted in Canada, a country with diverse ethnicities, has shown that different ethnic groups are disproportionately affected by type 2 diabetes in adolescents [23]. This disproportion was also evident in a study with adults conducted in England, whereby the minority ethnic groups displayed a higher prevalence of pre-diabetes [24].

Interestingly, South Africa, also known as the "rainbow nation", has a significant mixture of ethnicities, but whether certain ethnic groups in the country are disproportionally diagnosed with pre-diabetes remains unknown. Furthermore, there seems to be a paucity of pre-diabetes-related research work done within the southern African scale. Therefore, the overall prevalence of pre-diabetes in a South African population of mixed ethnicities remains uncertain or minimal.

1.1 Research question

  1. What is the prevalence of pre-diabetes, and are any ethnic groups disproportionally affected by pre-diabetes in South Africa?

  2. What are the common correlates of pre-diabetes?

1.2 Objectives

  1. To determine the prevalence of pre-diabetes in the adult population of mixed ethnicities.

  2. To determine the common correlates of pre-diabetes.

2. Methods

2.1 Design

This systemic review protocol has been prepared following the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) Protocols 2015 guidelines shown in S1 Table. This review was registered in the PROSPERO International Prospective Register of systematic reviews, registration number CRD42020182430.

2.2 Setting

South Africa is a country on the southernmost tip of the African continent. South Africa is the largest country in Southern Africa, with over 58 million people.

2.3 Criteria for considering studies for the review

2.3.1. Category of study

The studies considered for this review consisted of cross-sectional population-based studies, prospective or retrospective cohort studies and population-based surveys that report on the prevalence of pre-diabetes and how different ethnicities are affected. Also, a minimum of 100 participants had to be included in these studies. Furthermore, the most up-to-date and comprehensive version was selected for studies reported in more than one report.

2.3.2. Types of participants

The study participants included adults (≥18) located in South Africa, registered citizens who are Black, Coloured, Indian/Asian or White. The participants used in the studies had to be clinically diagnosed with pre-diabetes using the ADA or WHO diagnosis criteria.

2.3.3. The outcome of interest

Studies included in this review had to report the prevalence of pre-diabetes with sufficient data to calculate this estimate. Studies lacking primary data were excluded if the information was not provided after contacting authors at least twice.

2.3.4. Diagnosis criteria

The diagnosis criteria defined by the American diabetes association (ADA) and the World Health Organization (WHO) were considered. Accordingly, the diagnosis is determined by observing impaired fasting glucose (IFG), impaired glucose tolerance (IGT), and elevated glycosylated haemoglobin (HbA1c). IFG is defined as the fasting plasma glucose (FPG) of 6.1–6.9 mmol/L. IGT is defined as the two-hour plasma glucose of 7.8–11.0 mmol/L after the ingestion of 75 g of oral glucose load or a combination of both the IGT and the IFG recorded during the oral glucose tolerance test (OGTT). Any study that lacked a clear method description had to be excluded if, after contacting authors at least twice, the information was not provided.

2.4 Search strategy

Two independent (AMS & AK) reviewers conducted a comprehensive search of databases to find all related articles published on diabetes mellitus and pre-diabetes in South Africa from 2000 to 2020, regardless of the language of publication. The databases screened included MEDLINE through PubMed, Google Scholar, Web of Science and African Journals Online. The following Medical Subject Heading in our search strategy: “Pre-diabetes,” “South Africa,” “Prevalence,” “Type 2 diabetes mellitus,” “Glycated Hemoglobin,” “Impaired fasting glucose,” and “Impaired glucose tolerance.” A detailed method is shown in the search strategy in S2 Table. The Mendeley referencing manager (V.1.19.10) was used to remove duplicates. Moreover, hand searching was done to identify other eligible studies not indexed in the databases, especially in the included studies’ bibliography and relevant literature reviews.

2.5 Selection of included study

Two independent reviewers (AMS & AK) selected applicable studies. Each reviewer independently screened the titles, abstracts and full texts to acquire studies they consider relevant.

2.6 Appraisal of the quality of included studies

The methodological quality of included studies for prevalence estimates was assessed using an adapted version of the risk of bias tool for prevalence studies developed by Hoy and colleagues. A score of 0–4, 5–7, or 8–10 rated the risk of bias as high, moderate, or low, respectively. Two investigators (AMS & AK) independently assessed the study quality, with disagreements resolved by consensus or arbitration by a third review author (NM).

2.7 Analysis

A descriptive analysis of the eligible studies was first undertaken in the review investigation. The pooled proportion and 95% confidence interval (CI) were taken as the effect size. The normal distribution of data was validated using the D’Agostino & Pearson omnibus normality test. After that, a Meta-analysis was undertaken using a random-effects model (to account for heterogeneity) conducted using the MetaXL (www.epigear.com) add-in for Microsoft Excel. Using MetaXL, we calculated the I2 statistics to assess heterogeneity between estimates. The I2 value describes the percentage of variation not because of chance or sampling error across studies. If the I2 value is higher than 75%, then the heterogeneity between studies is deemed high. We used the 95% CI to calculate a pooled prevalence figure.

Any possible influences on prevalence estimates were investigated using subgroup analyses. We assessed the impact on estimates of the following study-level variables identified a priori as potential sources of variation in the calculations of prevalence: [1] risk of bias, [2] geographical location, and [3] data collection method. We classified studies as being either at low risk of bias (low risk of both participation and outcome measurement bias) or moderate-to-high risk of bias (moderate or high risk of either participation or outcome measurement bias).

3. Results

3.1 Study selection

The initial search resulted in a total of 995 articles detected (Fig 1). The last search date was on the 7th of September 2021. After that, the titles and abstracts had to be screened for eligibility. Consequently, 950 articles had to be extracted due to duplication and being unrelated. Then the full-text assessment of the remaining 45 articles was conducted, which resulted in 13 articles that met the eligibility criteria.

Fig 1. Presents the procedure followed for identifying and selecting studies included in the review.

Fig 1

Open in a new tab

3.2 Appraisal of the quality of included studies

Hoy and colleagues’ risk of bias assessment for prevalence studies was used. Seven out of the 13 articles had a low risk of bias; out of the remaining seven articles, six had a moderate risk of bias, and one had a high risk of bias (Table 1). All the studies with a moderate to high risk of bias were not randomised.

Table 1. Presents the summary of pre-diabetes prevalence in all the considered sub-groups.

Except for Limpopo, the more industrialised provinces, such as KwaZulu-Natal (KZN), Gauteng and Cape Town/Western Cape, tend to have a higher pre-diabetes prevalence. The Coloured and Indian populations have the highest prevalence of pre-diabetes. The risk of bias in most studies was low or moderate. The male and female participants have a similar prevalence of pre-diabetes. The IFG detected more pre-diabetic cases than IGT.

Group Studies Participants Cases Prevalence % (95%CI) I2% p-Egger test
By province 0,009
KZN 3 3567 462 12,96 (-21,8–47,7) 99
EC 4 2003 196 9,81 (-0,8–20,4) 97
CPT 3 2362 364 15,42 (7,8–23,1) 84
Free state 1 552 35 6,3 -
Gauteng 1 142 35 24,7 -
Limpopo 1 713 342 48,0 -
By race 0,009
Black 10 6670 924 13,85 (4, - 23,6) 99
Coloured 2 1291 230 17,8 64
Indian 1 1378 401 29,10 (26,6–31,5) -
By risk of bias
Low 7 6288 1049 16,69 (1,5–31,9) 99
Moderate 5 2823 441 15,62 (7,4–23,8) 95
High 1 228 14 6,14 (3,1–9,2) -
By gender 0,000
Male 11 3066 586 19,10 (3,5–11,1) 98,13
Female 12 6472 1294 19,99 (8,8–31,2) 98,95
By diagnosis 0,009
IFG 5 2894 526 18,19 (-3,2–39,6) 427,94
IGT 8 6445 895 13,89 (5,8–22,0) 553,10
Open in a new tab

3.3 Pre-diabetes prevalence

In a pooled sample of 5257 participants, the combined effect size for the prevalence of pre-diabetes is 15,56% in the South African population (Fig 2). The heterogeneity observed in the forest plot is 98,86%.

Fig 2. Presents a forest plot of the summary of the analysis of prediabetes prevalence in South Africa.

Fig 2

Open in a new tab

The diagnosis was determined by either IFG or IGT test. In a pooled sample of 9339 participants, the prevalence of prediabetes was 15,56%, with a heterogeneity of 98,86%.

3.4 Prevalence of pre-diabetes stratified by sex and age

The results show that the female-to-male ratio is 1,18 (Fig 3). Therefore, the probability of developing pre-diabetes in females is higher by 0,18 (or 18%) than in males. In Fig 4, group A and B results show that the prevalence of pre-diabetes will generally increase with age.

Fig 3. Presents the prevalence of pre-diabetes stratified by sex in the South African population.

Fig 3

Open in a new tab

The study conducted by A Mtintsilana only had female participants. The overall female-to-male ratio is 1,18.

Fig 4. Presents the prevalence of pre-diabetes stratified by age.

Fig 4

Open in a new tab

Except for the 18–29 age range in group B, the proportion of individuals with prediabetes tends to increase with increasing age.

3.5 Summary of sub-group results

The following results are seen in Table 1. The findings show that according to the geographical location, the province of Limpopo, represented by a single study, has an alarming 48,0% prevalence of pre-diabetes, which is the highest. Other provinces represented by single research include Gauteng (24,7%) and Free State (6,3%). Of the provinces that had more than one study conducted in it, the Western cape province, represented by Cape town, had the highest prevalence of pre-diabetes (15,4%), followed by KwaZulu-Natal (12,96%) and Eastern cape (9,81%). The prevalence of pre-diabetes according to race reveals that the Indian population has a proportion of 29,01%. The Indian population was followed by the Coloured at 17,38% and then the Black population at 13,8%. The risk of bias outcome shows that the pooled data for the group of studies with low risk is 16,7%, 15,6% for the moderate risk group and 6,1% for the high-risk group that is only represented by one study. According to the diagnosis method, the prevalence of pre-diabetes was recorded to be 18,2% in the studies that used the impaired fasting glucose test and 13,9% using the impaired glucose tolerance.

3.6 Correlates of pre-diabetes

The results are recorded in Table 2. From the identified correlates, hypertension has the highest total proportion of 46,8% in the pool of studies elected. People who live a sedentary lifestyle have the second highest total proportion of 43,4% in the pooled studies. In addition, the proportion of obesity (39,1%) and overweight (36,5%) is high in the population. A high number of smokers (26,3%) and people who drink alcohol (30,6%) are represented in the review. Family history of diabetes was represented by a single study that reported that 32,8% of the participants had a history of diabetes. Triglyceride levels had a mean value of 1,43 mmol/L, whilst total cholesterol and LDL had mean values of 4,47 and 2,75 mmol/L.

Table 2. Shows the proportion of risk factors associated with pre-diabetes.

Studies obesity overweight hypertension tobacco alcohol Triglycerides Chol (mmol/l): Total & LDL Family history Sedentary lifestyle
Matshipi et al., 2017 - - - - - - - - -
Adedokun et al., 2019 - - - 49.4 - - - -
Erasmus et al., 2012 - - - 44.4 28.4 - - - -
Mtintsilana et al., 2019 70.4 21.1 - - - - - - -
Peer et al., 2015 63 58 49 28 33 - 4.4 & 3.0 - -
Hird et al., 2016 37.7 60.8 28.9 19.2 14.3 1.4 4.3 & 2.3 32.8 46.5%
Erasmus et al., 2001 10 10 - - - - - - -
Prakaschandra et al., 2016 10,4 - 79 24,9 - 1.8 3.35 - -
Kengne et al., 2017 - - - - - - 3.3 & 5.2 - -
Motala et al., 2008 - 64 64 - - 1.1 4.1 & 2.4 - -
Groenewald et al., 2009 32.1 20.8 - - - - - - 9.1%
Mkanzi et al., 2020 44 33 11 - - - - - -
Owolabi et al., 2017 45.2 24 49 15 28 - - - 74.7%
Mean 39,1 36,5 46,8 26,3 30,62 1,43 4,27 & 2,75 32,8 43.4
Open in a new tab

4. Discussion

According to the department of Statistics of South Africa, the Republic of South Africa has a population of slightly over 60 million [25]. Therefore, the present meta-analysis showed that the overall prevalence of pre-diabetes was 15,56% in the South African population, which translates to over 9 million people with pre-diabetes. Interestingly, pre-diabetes diagnosis using the impaired fasting glucose criteria (IFG) had a higher prevalence of 18,2% compared to studies that used the impaired glucose tolerance test (IGT), which recorded 13,9%. Consequently, the heterogeneity recorded in the forest plot was 98,86%, indicating a high variability between the studies. We speculate that one reason for the high heterogeneity is the differences in the diagnosis methods utilised across the selected studies.

Differences in prevalence between IFG and IGT confirm the different pathophysiological mechanisms that contribute to these glucose homeostasis disorders. Some literature suggests that IFG is seen after impaired glucose tolerance IGT is observed [11, 26, 27]. Relative to IGT, the IFG is associated with a more significant increase in future T2DM risk [11]. Hence, IFG will generally be seen in a slightly more advanced stage of pre-diabetes prognosis relative to IGT [11]. However, compensatory mechanisms such as increased insulin secretion by the pancreatic beta-cells can delay the development of pre-diabetes [28]. Therefore, these compensatory mechanisms should be considered, as they may be more robust in specific individuals, allowing them to bypass the early phase of IGT. Hence, it is plausible that at this moment, a speculate that a more significant number of people with pre-diabetes remain undiagnosed either because they do not go for health screening or because the clinicians may prefer to use only IFG to determine pre-diabetes. By doing so, they miss many pre-diabetic individuals according to the IGT criteria.

The sex of the participant seems to play a slight role in developing pre-diabetes. The results in Fig 2 indicate that females have an 18% greater chance of developing pre-diabetes when compared to males. This contrasts with what some literature suggests: that males are more susceptible to diabetes than females [29–31]. Their justification is that men tend to store fat in their organs, like the liver, compared to women, who store fat mainly on the surface layer, such as the hip and thighs [31]. However, literature has also shown that females are more prone to developing IFG than males, independent of age [32, 33]. This suggests that females may have more robust protective mechanisms that delay the onset of T2D. A European study corroborated that men are often diagnosed with T2D earlier than women [32, 34]. Therefore, the higher prevalence of pre-diabetes observed in women can be explained by their greater susceptibility to developing pre-diabetes.

Another interesting factor that the review looked at is age. The findings in this review show that the association between age and the prevalence of pre-diabetes are directly proportional. The results are consistent with the literature as the prevalence of pre-diabetes rises with increasing age [24, 35, 36]. The plausible explanation for the correlation between age and prevalence is that people tend to live a more sedentary lifestyle as they grow older. A study by Zoran Milanović et al. revealed that relative to the young elderly, there is a reduction in physical activity amongst the old elderly [37]. The decline in physical activity was attributed to decreased muscle strength in both upper and lower limbs and changes in body-fat percentage [37]. However, the high prevalence observed in the 18–29 age group in Fig 4 can be attributed to the study by Sekgala et al., which reported on the 18–29 age group only [38]. Therefore, it is plausible to expect a similar trend had the study by Sekgala included the older age groups.

The prevalence of pre-diabetes according to geographical location shows that the Limpopo and Gauteng provinces have the highest prevalence of 48% and 24,8%, respectively. However, this cannot be taken as conclusive data because these provinces have a small sample size and are represented by a single study. Therefore, more prevalence studies are required in these provinces. The outcomes of the prevalence of pre-diabetes according to the geographical location are more credible in the provinces with multiple studies. These provinces include the province of the Western Cape, represented by Cape Town, which had the highest prevalence of 15,42%, followed by KwaZulu-Natal with 12,96% and Eastern cape with 9,81%. However, ethnicity is known to play a role in the prevalence of diabetes.

The prevalence of pre-diabetes across different ethnic groups in South Africa suggests a genetic predisposition for developing pre-diabetes. The Indian population have the highest prevalence of 29,01%, followed by the coloured community with 17,38% and the black population with 13,8%. Therefore, ethnicity plays a significant role in predisposition to developing pre-diabetes. There is increasing evidence in the literature on how epigenetic factors play an essential role in the development of T2D [39, 40]. Epigenetics can be described as transmissible alterations in gene functions that arise with no changes in their nucleotide sequence [41]. Epigenetic markers like miRNAs and methylation are shown to be involved in the pathogenesis of diabetes and may explain why some ethnic groups are disproportionally affected by pre-diabetes [23, 40, 42]. Hence, further studies appraising the role of epigenetics in developing pre-diabetes are needed for the population of South Africa. Furthermore, pre-diabetes is associated with numerous other medical conditions.

Unsurprisingly, the prevalence of pre-diabetes correlates with high occurrences of hypertension, obesity, overweight, and a sedentary lifestyle. These risk factors are well documented in the literature to be associated with the development of diabetes [24, 43, 44]. Hence, there is expected to be a high pre-diabetes prevalence whenever these correlates are high in a population. Therefore, we must not look at pre-diabetes as an isolated condition; instead, we need to monitor its risk factors, which play a significant role in the onset and prognosis of pre-diabetes. Derek Weycker et al. have shown that regardless of BMI, age, and sex, all people with hypertension are at a considerable risk of becoming diabetic [45]. Also, the sedentary lifestyle over the years has risen with the increasing urbanisation and consumption of western fast foods, which according to the literature, is directly proportional to the rise in pre-diabetes prevalence and all course mortality [46, 47]. A sedentary lifestyle causes an imbalance in calorie intake, resulting in a greater intake than output. This imbalance causes the body to store the extra energy source as fats which accumulate and cause insulin resistance that leads to pre-diabetes and type 2 diabetes [48, 49]. Likewise, the obesity and overweight association with diabetes is well established [50]. Both conditions of obesity indicate early signs of insulin resistance and can result in the development of diabetes if unattended. Therefore, when assessing the prevalence of pre-diabetes in a particular location, these associated risk factors must also be monitored to identify those at risk.

5. Limitations

One of the limitations of this study is that only seven of the 13 eligible studies had a low level of risk. This suggests that more credible studies are needed to have a pool of studies that will generate a more reliable overall prevalence in the country. Furthermore, some utilised the outdated version of the WHO diagnostic criteria for impaired glucose tolerance and impaired fasting glucose. The lack of a universal definition for determining pre-diabetes is also a limitation for this review because different studies utilised different criteria for deciding pre-diabetes.

6. Conclusion

The selected studies did not apply the same criteria for diagnosing pre-diabetes and some used outdated measures. Consequently, there is a need for a universal diagnostic marker for pre-diabetes that will improve accuracy when comparing and pooling epidemiological studies. Furthermore, the present review findings are concerning because a high prevalence of pre-diabetes poses a significant health care burden. Pre-diabetes is associated with metabolic disorders and is the frontal risk factor for developing the more harmful type 2 diabetes. Thus, there is a gap for more prevalence studies on prediabetes that will use current diagnostic criteria for pre-diabetes and reveal updated data on the prevalence of pre-diabetes.

Additionally, as seen in T2D, there appears to be a correlation between a high prevalence of pre-diabetes and hypertension, obesity and a sedentary lifestyle. Screenings done in the hospitals should therefore be holistic by including markers for pre-diabetes and associated correlates. Finally, the findings suggest that clinicians should put in place preventative measures for preventing the progression from pre-diabetes to type 2 diabetes and have more clinical outreaches to identify early those who have pre-diabetes.

Supporting information

S1 Table. PRISMA-P 2015 checklist.

(DOCX)

Click here for additional data file. (40.9KB, docx)
S2 Table. Search strategy (PubMed).

(DOCX)

Click here for additional data file. (20.5KB, docx)

Acknowledgments

The authors would like to acknowledge everyone in the Endorince research group for their academic and moral support.

Data Availability

All relevant data are within the paper and its Supporting information files.

Funding Statement

National Research Foundation funded AM for the study. The funders had no role in study design and manuscript preparation (Grant number:121558).

References

  • 1.Beulens J, Rutters F, Rydén L, Schnell O, Mellbin L, Hart H, et al. Risk and management of pre-diabetes. European Journal of Preventive Cardiology. 2020;26(2_suppl):47–54. [DOI] [PubMed] [Google Scholar]
  • 2.Edwards CM, Cusi K. Prediabetes: A Worldwide Epidemic. Endocrinol Metab Clin North Am. 2016;45(4):751–64. doi: 10.1016/j.ecl.2016.06.007 [DOI] [PubMed] [Google Scholar]
  • 3.Tabák AG, Herder C, Rathmann W, Brunner EJ, Kivimäki M. Prediabetes: a high-risk state for diabetes development. Lancet. 2012;379(9833):2279–90. doi: 10.1016/S0140-6736(12)60283-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Wilson ML. Prediabetes: beyond the borderline. Nursing Clinics. 2017;52(4):665–77. doi: 10.1016/j.cnur.2017.07.011 [DOI] [PubMed] [Google Scholar]
  • 5.Ford ES, Zhao G, Li C. Pre-Diabetes and the Risk for Cardiovascular Disease: A Systematic Review of the Evidence. Journal of the American College of Cardiology. 2010;55(13):1310–7. doi: 10.1016/j.jacc.2009.10.060 [DOI] [PubMed] [Google Scholar]
  • 6.Brannick B, Wynn A, Dagogo-Jack S. Prediabetes as a toxic environment for the initiation of microvascular and macrovascular complications. Experimental Biology and Medicine. 2016;241(12]:1323–31. doi: 10.1177/1535370216654227 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Palladino R, Tabak AG, Khunti K, Valabhji J, Majeed A, Millett C, et al. Association between pre-diabetes and microvascular and macrovascular disease in newly diagnosed type 2 diabetes. BMJ Open Diabetes Research & Care. 2020;8(1):e001061. doi: 10.1136/bmjdrc-2019-001061 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Barry E, Roberts S, Oke J, Vijayaraghavan S, Normansell R, Greenhalgh T. Efficacy and effectiveness of screen and treat policies in prevention of type 2 diabetes: systematic review and meta-analysis of screening tests and interventions. BMJ. 2017:i6538. doi: 10.1136/bmj.i6538 [DOI] [PubMed] [Google Scholar]
  • 9.Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, Brenneman AT, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet (London, England). 2009;374(9702):1677–86. doi: 10.1016/S0140-6736(09)61457-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Nathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, Pratley R, et al. Impaired Fasting Glucose and Impaired Glucose Tolerance: Implications for care. Diabetes Care. 2007;30(3):753–9. doi: 10.2337/dc07-9920 [DOI] [PubMed] [Google Scholar]
  • 11.Abdul-Ghani M, DeFronzo RA, Jayyousi A. Prediabetes and risk of diabetes and associated complications: impaired fasting glucose versus impaired glucose tolerance: does it matter? Current opinion in clinical nutrition and metabolic care. 2016;19(5):394–9. doi: 10.1097/MCO.0000000000000307 [DOI] [PubMed] [Google Scholar]
  • 12.Abdul-Ghani MA, Tripathy D, DeFronzo RA. Contributions of β-Cell Dysfunction and Insulin Resistance to the Pathogenesis of Impaired Glucose Tolerance and Impaired Fasting Glucose. Diabetes Care. 2006;29(5):1130–9. [DOI] [PubMed] [Google Scholar]
  • 13.Saltiel AR, Pessin JE. Insulin signaling pathways in time and space. Trends in Cell Biology. 2002;12(2):65–71. doi: 10.1016/s0962-8924(01)02207-3 [DOI] [PubMed] [Google Scholar]
  • 14.Boucher J, Kleinridders A, Kahn CR. Insulin receptor signaling in normal and insulin-resistant states. Cold Spring Harb Perspect Biol. 2014;6(1). doi: 10.1101/cshperspect.a009191 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Tuso P. Prediabetes and lifestyle modification: time to prevent a preventable disease. Perm J. 2014;18(3):88–93. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Heianza Y, Arase Y, Fujihara K, Tsuji H, Saito K, Hsieh SD, et al. Screening for pre-diabetes to predict future diabetes using various cut-off points for HbA(1c) and impaired fasting glucose: the Toranomon Hospital Health Management Center Study 4 (TOPICS 4). Diabet Med. 2012;29(9):e279–85. doi: 10.1111/j.1464-5491.2012.03686.x [DOI] [PubMed] [Google Scholar]
  • 17.Zimmet PZ, Magliano DJ, Herman WH, Shaw JE. Diabetes: a 21st century challenge. Lancet Diabetes Endocrinol. 2014;2(1):56–64. doi: 10.1016/S2213-8587(13)70112-8 [DOI] [PubMed] [Google Scholar]
  • 18.Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res Clin Pract. 2019;157:107843. doi: 10.1016/j.diabres.2019.107843 [DOI] [PubMed] [Google Scholar]
  • 19.Organisation WH. Global burden of diabetes. Global report on diabetes World Health Organization. 2016. [Google Scholar]
  • 20.Vistisen D, Witte DR, Brunner EJ, Kivimäki M, Tabák ÁG, Jørgensen ME, et al. Risk of Cardiovascular Disease and Death in Individuals With Prediabetes Defined by Different Criteria: The Whitehall II Study. Diabetes Care. 2018;41:899–906. doi: 10.2337/dc17-2530 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Roeyen G, Jansen M, Chapelle T, Bracke B, Hartman V, Ysebaert D, et al. Diabetes mellitus and pre-diabetes are frequently undiagnosed and underreported in patients referred for pancreatic surgery. A prospective observational study. Pancreatology. 2016;16(4):671–6. doi: 10.1016/j.pan.2016.04.032 [DOI] [PubMed] [Google Scholar]
  • 22.Control CfD, Prevention. National Diabetes Statistics Report, 2020. Atlanta, GA: Centers for Disease Control and Prevention, US Dept of Health and Human Services. 2020.
  • 23.Spurr S, Bally J, Bullin C, Allan D, McNair E. The prevalence of undiagnosed Prediabetes/type 2 diabetes, prehypertension/hypertension and obesity among ethnic groups of adolescents in Western Canada. BMC pediatrics. 2020;20(1):1–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Mainous AG, Tanner RJ, Baker R, Zayas CE, Harle CA. Prevalence of prediabetes in England from 2003 to 2011: population-based, cross-sectional study. BMJ Open. 2014;4(6):e005002–e. doi: 10.1136/bmjopen-2014-005002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.SA S. Mid-year population estimates. In: Africa SS, editor. 2021. [Google Scholar]
  • 26.Snehalatha C, Ramachandran A, Sivasankari S, Satyavani K, Vijay V. Insulin secretion and action show differences in impaired fasting glucose and in impaired glucose tolerance in Asian Indians. Diabetes/metabolism research and reviews. 2003;19(4):329–32. doi: 10.1002/dmrr.388 [DOI] [PubMed] [Google Scholar]
  • 27.Hong J, Gui M, Gu W, Zhang Y, Xu M, Chi Z, et al. Differences in insulin resistance and pancreatic B-cell function in obese subjects with isolated impaired glucose tolerance and isolated impaired fasting glucose. Diabetic medicine: a journal of the British Diabetic Association. 2008;25(1):73–9. doi: 10.1111/j.1464-5491.2007.02329.x [DOI] [PubMed] [Google Scholar]
  • 28.Halban PA, Polonsky KS, Bowden DW, Hawkins MA, Ling C, Mather KJ, et al. β-cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment. The Journal of Clinical Endocrinology & Metabolism. 2014;99(6):1983–92. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, et al. prevalence of diabetes among men and women in China. N Engl J Med. 2010;362(12):1090–101. doi: 10.1056/NEJMoa0908292 [DOI] [PubMed] [Google Scholar]
  • 30.Thakur R. Unequal burden of equal risk factors of diabetes between different gender in India: a cross-sectional analysis. Sci Rep. 2021;11(1):1–12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Nordström* A, Hadrévi J, Olsson T, Franks PW, Nordström P. Higher prevalence of type 2 diabetes in men than in women is associated with differences in visceral fat mass. The Journal of Clinical Endocrinology & Metabolism. 2016;101(10):3740–6. doi: 10.1210/jc.2016-1915 [DOI] [PubMed] [Google Scholar]
  • 32.Kautzky-Willer A, Harreiter J, Pacini G. Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus. Endocr Rev. 2016;37(3):278–316. doi: 10.1210/er.2015-1137 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Aguirre F BA, Cho NH, Dahlquist G, Dodd S, Dunning T et al. IDF Diabetes Atlas: Sixth edition. Sixth ed. 2013:160 [Google Scholar]
  • 34.Logue J, Walker J, Colhoun H, Leese G, Lindsay R, McKnight J, et al. Do men develop type 2 diabetes at lower body mass indices than women? Diabetologia. 2011;54(12):3003–6. doi: 10.1007/s00125-011-2313-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Skyler JS, Oddo C. Diabetes trends in the USA. Diabetes/Metabolism Research and Reviews. 2002;18(S3):S21–S6. doi: 10.1002/dmrr.289 [DOI] [PubMed] [Google Scholar]
  • 36.Mihardja L, Delima Manz HS, Ghani L, Soegondo S. Prevalence and determinants of diabetes mellitus and impaired glucose tolerance in Indonesia (a part of basic health research/Riskesdas). Acta Med Indones. 2009;41(4):169–74. [PubMed] [Google Scholar]
  • 37.Milanović Z, Pantelić S, Trajković N, Sporiš G, Kostić R, James N. Age-related decrease in physical activity and functional fitness among elderly men and women. Clin Interv Aging. 2013;8:549–56. doi: 10.2147/CIA.S44112 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Sekgala M, Monyeki K, Mogale A, Mchiza Z, Parker W, Choma S, et al. The risk of metabolic syndrome as a result of lifestyle among Ellisras rural young adults. J Hum Hypertens. 2018;32(8):572–84. doi: 10.1038/s41371-018-0076-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Toperoff G, Aran D, Kark JD, Rosenberg M, Dubnikov T, Nissan B, et al. Genome-wide survey reveals predisposing diabetes type 2-related DNA methylation variations in human peripheral blood. Human Molecular Genetics. 2012;21(2):371–83. doi: 10.1093/hmg/ddr472 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Wander PL, Enquobahrie DA, Bammler TK, Srinouanprachanh S, Macdonald J, Kahn SE, et al. Short Report: Circulating microRNAs are associated with incident diabetes over 10 years in Japanese Americans. Scientific Reports. 2020;10(1). doi: 10.1038/s41598-020-63606-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Zhang XA, Ho SM. Epigenetics meets endocrinology. J Mol Endocrinol. 2011;46(1):R11–R32. doi: 10.1677/jme-10-0053 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Gallo W, Esguerra JLS, Eliasson L, Melander O. miR-483-5p associates with obesity and insulin resistance and independently associates with new onset diabetes mellitus and cardiovascular disease. PLOS ONE. 2018;13(11):e0206974. doi: 10.1371/journal.pone.0206974 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Plantinga LC, Crews DC, Coresh J, Miller ER, Saran R, Yee J, et al. Prevalence of Chronic Kidney Disease in US Adults with Undiagnosed Diabetes or Prediabetes. Clinical Journal of the American Society of Nephrology. 2010;5(4):673–82. doi: 10.2215/CJN.07891109 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Wang R, Zhang P, Li Z, Lv X, Cai H, Gao C, et al. The prevalence of pre-diabetes and diabetes and their associated factors in Northeast China: a cross-sectional study. Sci Rep. 2019;9(1). doi: 10.1038/s41598-019-39221-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Weycker D, Nichols GA, O’Keeffe-Rosetti M, Edelsberg J, Vincze G, Khan ZM, et al. Excess risk of diabetes in persons with hypertension. J Diabetes Complications. 2009;23(5):330–6. doi: 10.1016/j.jdiacomp.2008.04.002 [DOI] [PubMed] [Google Scholar]
  • 46.Lam DW, LeRoith D. The worldwide diabetes epidemic. Current Opinion in Endocrinology, Diabetes and Obesity. 2012;19(2):93–6. doi: 10.1097/MED.0b013e328350583a [DOI] [PubMed] [Google Scholar]
  • 47.Dunstan DW, Barr ELM, Healy GN, Salmon J, Shaw JE, Balkau B, et al. Television Viewing Time and Mortality. Circulation. 2010;121(3):384–91. [DOI] [PubMed] [Google Scholar]
  • 48.Yaribeygi H, Maleki M, Sathyapalan T, Jamialahmadi T, Sahebkar A. Obesity and Insulin Resistance: A Review of Molecular Interactions. Current Molecular Medicine. 2021;21(3):182–93. doi: 10.2174/1566524020666200812221527 [DOI] [PubMed] [Google Scholar]
  • 49.Guo CM, Zhou QG, Zhang DD, Qin P, Li QM, Tian G, et al. Association of total sedentary behaviour and television viewing with risk of overweight/obesity, type 2 diabetes and hypertension: A dose-response meta-analysis. Diabetes Obes Metab. 2020;22(1):79–90. doi: 10.1111/dom.13867 [DOI] [PubMed] [Google Scholar]
  • 50.Zhang H, Ni J, Yu C, Wu Y, Li J, Liu J, et al. Sex-Based Differences in Diabetes Prevalence and Risk Factors: A Population-Based Cross-Sectional Study Among Low-Income Adults in China. Frontiers in Endocrinology. 2019;10. [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Muhammad Sajid Hamid Akash

Transfer Alert

This paper was transferred from another journal. As a result, its full editorial history (including decision letters, peer reviews and author responses) may not be present.

4 Aug 2022

PONE-D-22-14937Prevalence and correlates of pre-diabetes in adults of mixed ethnicities in the South African population: A Systematic Review and Meta-analysis

PLOS ONE

Dear Dr. Sosibo,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

I have received the reports from our advisors on your manuscript which you submitted to PLOS ONE.

Based on the comments received, I feel that your manuscript could be reconsidered for publication should you be prepared to incorporate major revisions.

When preparing your revised manuscript, you are asked to carefully consider the reviewer comments below and submit a list of responses to the comments.

Editor Comments: There is a huge list of grammatical mistakes and syntax errors. The paper should be checked by a professional speaker of English before complete acceptance.

Please submit your revised manuscript by Sep 18 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Muhammad Sajid Hamid Akash

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for stating the following in the Acknowledgments Section of your manuscript: 

   "I would like to acknowledge the National Research Foundation for funding the study (Grant number:121558) and everyone in the Endorince research group fortheir academic and technical support."

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. 

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows: 

  "National Research Foundation funded AM for the study. The funders had no role in study design and manuscript preparation (Grant number:121558)"

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

3. We note you have included a table to which you do not refer in the text of your manuscript. Please ensure that you refer to Table 2 in your text; if accepted, production will need this reference to link the reader to the Table.

4. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information. 

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The author presented an original article on “Prevalence and correlates of pre-diabetes in adults of mixed ethnicities in the South African population: A Systematic Review and Meta-analysis”. The manuscript needs to be improved regarding the following aspects.

• More details are required to explain the association between key points and the conclusion.

• Comprehensively explain the disease pathogenesis, its associated complications and the therapeutic interventions to strengthen your study e.g., https://doi.org/10.1002/jcb.26174 , https://doi.org/10.1111/jfbc.14228 and https://doi.org/10.1615/CritRevEukaryotGeneExpr.2015013358 ,

• Results are not well explained and comprehensively described.

• More graphical representations of the results should be included in the manuscript.

• More description is required in the discussion section to elaborate the association between the results and the literature review.

• Many references are missing or inconsistent in format.

• The format of the manuscript is inconsistent and is required per the requirement of the journal.

• There are some grammatical mistakes in the manuscript, such as verbs and prepositions. The manuscript needs extensive review by an author.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Sumbal Rasheed

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2022 Nov 29;17(11):e0278347. doi: 10.1371/journal.pone.0278347.r002

Author response to Decision Letter 0

12 Sep 2022

The authors would like to thank the editor and reviewer for their comments that helped improved the manuscript. All the comments were thoroughly attended to as seen in the uploaded rebuttal letter and highlighted manuscript.

Attachment

Submitted filename: PLOS ONE SR PAPER REBUTTAL LETTER.docx

Click here for additional data file. (24.1KB, docx)

Decision Letter 1

Paolo Magni

15 Nov 2022

Prevalence and correlates of pre-diabetes in adults of mixed ethnicities in the South African population: A Systematic Review and Meta-analysis

PONE-D-22-14937R1

Dear Dr. Aubrey Mbulelo Sosibo,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Paolo Magni

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

All comments have been addressed

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Sumbal Rasheed

**********

Acceptance letter

Paolo Magni

17 Nov 2022

PONE-D-22-14937R1

Prevalence and correlates of pre-diabetes in adults of mixed ethnicities in the South African population: A Systematic Review and Meta-analysis

Dear Dr. Sosibo:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Prof. Paolo Magni

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Table. PRISMA-P 2015 checklist.

    (DOCX)

    Click here for additional data file. (40.9KB, docx)
    S2 Table. Search strategy (PubMed).

    (DOCX)

    Click here for additional data file. (20.5KB, docx)
    Attachment

    Submitted filename: PLOS ONE SR PAPER REBUTTAL LETTER.docx

    Click here for additional data file. (24.1KB, docx)

    Data Availability Statement

    All relevant data are within the paper and its Supporting information files.

    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES